Qing Zheng, Zhenqi Gong, Baizhi Li, Huaiming Wang, Shaoxiong Lin
{"title":"基于抗体依赖性细胞吞噬作用特征的开发与验证：胃癌预后风险模型","authors":"Qing Zheng, Zhenqi Gong, Baizhi Li, Huaiming Wang, Shaoxiong Lin","doi":"10.17219/acem/189914","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Accumulating evidence has supported the effect of antibody-dependent cellular phagocytosis (ADCP) on the tumor microenvironment (TME) and cancer therapy. However, an ADCP-based signature to predict the prognosis of gastric cancer (GC) has not been established.</p><p><strong>Objectives: </strong>We aimed to develop an ADCP-based signature to improve the prognosis prediction of GC.</p><p><strong>Material and methods: </strong>Antibody-dependent cellular phagocytosis genes that exhibited a differential expression were characterized, followed by the construction and validation of the ADCP-based signature. The potential association between the ADCP-based signature and TME was explored, and the features of the signature genes were investigated. Finally, a predictive nomogram was established based on the ADCP-based signature.</p><p><strong>Results: </strong>Four ADCP-related genes, MKNK2, VCAN, LRAT, and GNGB, were identified to construct the ADCP-based signature, and a high ADCP score predicted an unfavorable prognosis in GC patients (p < 0.05). The ADCP-based signature was significantly associated with immune cells, immune checkpoints and immune signaling pathways (p < 0.05). Gastric cancer patients with high ADCP scores benefited less from immunotherapy compared to those with low ADCP scores. A nomogram including age, stage and risk score of the ADCP-based signature was constructed to predict the 1-, 3- and 5-year survival probabilities, with an area under the curve (AUC) of 0.669, 0.675 and 0.685, respectively.</p><p><strong>Conclusions: </strong>The ADCP-based signature may serve as a new option for prognosis prediction and the personalized treatment of GC patients.</p>","PeriodicalId":7306,"journal":{"name":"Advances in Clinical and Experimental Medicine","volume":" ","pages":""},"PeriodicalIF":2.1000,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Development and validation of the antibody-dependent cellular phagocytosis-based signature: A prognostic risk model of gastric cancer.\",\"authors\":\"Qing Zheng, Zhenqi Gong, Baizhi Li, Huaiming Wang, Shaoxiong Lin\",\"doi\":\"10.17219/acem/189914\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Accumulating evidence has supported the effect of antibody-dependent cellular phagocytosis (ADCP) on the tumor microenvironment (TME) and cancer therapy. However, an ADCP-based signature to predict the prognosis of gastric cancer (GC) has not been established.</p><p><strong>Objectives: </strong>We aimed to develop an ADCP-based signature to improve the prognosis prediction of GC.</p><p><strong>Material and methods: </strong>Antibody-dependent cellular phagocytosis genes that exhibited a differential expression were characterized, followed by the construction and validation of the ADCP-based signature. The potential association between the ADCP-based signature and TME was explored, and the features of the signature genes were investigated. Finally, a predictive nomogram was established based on the ADCP-based signature.</p><p><strong>Results: </strong>Four ADCP-related genes, MKNK2, VCAN, LRAT, and GNGB, were identified to construct the ADCP-based signature, and a high ADCP score predicted an unfavorable prognosis in GC patients (p < 0.05). The ADCP-based signature was significantly associated with immune cells, immune checkpoints and immune signaling pathways (p < 0.05). Gastric cancer patients with high ADCP scores benefited less from immunotherapy compared to those with low ADCP scores. A nomogram including age, stage and risk score of the ADCP-based signature was constructed to predict the 1-, 3- and 5-year survival probabilities, with an area under the curve (AUC) of 0.669, 0.675 and 0.685, respectively.</p><p><strong>Conclusions: </strong>The ADCP-based signature may serve as a new option for prognosis prediction and the personalized treatment of GC patients.</p>\",\"PeriodicalId\":7306,\"journal\":{\"name\":\"Advances in Clinical and Experimental Medicine\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2024-11-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Advances in Clinical and Experimental Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.17219/acem/189914\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Clinical and Experimental Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.17219/acem/189914","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
Development and validation of the antibody-dependent cellular phagocytosis-based signature: A prognostic risk model of gastric cancer.
Background: Accumulating evidence has supported the effect of antibody-dependent cellular phagocytosis (ADCP) on the tumor microenvironment (TME) and cancer therapy. However, an ADCP-based signature to predict the prognosis of gastric cancer (GC) has not been established.
Objectives: We aimed to develop an ADCP-based signature to improve the prognosis prediction of GC.
Material and methods: Antibody-dependent cellular phagocytosis genes that exhibited a differential expression were characterized, followed by the construction and validation of the ADCP-based signature. The potential association between the ADCP-based signature and TME was explored, and the features of the signature genes were investigated. Finally, a predictive nomogram was established based on the ADCP-based signature.
Results: Four ADCP-related genes, MKNK2, VCAN, LRAT, and GNGB, were identified to construct the ADCP-based signature, and a high ADCP score predicted an unfavorable prognosis in GC patients (p < 0.05). The ADCP-based signature was significantly associated with immune cells, immune checkpoints and immune signaling pathways (p < 0.05). Gastric cancer patients with high ADCP scores benefited less from immunotherapy compared to those with low ADCP scores. A nomogram including age, stage and risk score of the ADCP-based signature was constructed to predict the 1-, 3- and 5-year survival probabilities, with an area under the curve (AUC) of 0.669, 0.675 and 0.685, respectively.
Conclusions: The ADCP-based signature may serve as a new option for prognosis prediction and the personalized treatment of GC patients.
期刊介绍：
Advances in Clinical and Experimental Medicine has been published by the Wroclaw Medical University since 1992. Establishing the medical journal was the idea of Prof. Bogumił Halawa, Chair of the Department of Cardiology, and was fully supported by the Rector of Wroclaw Medical University, Prof. Zbigniew Knapik. Prof. Halawa was also the first editor-in-chief, between 1992-1997. The journal, then entitled "Postępy Medycyny Klinicznej i Doświadczalnej", appeared quarterly.
Prof. Leszek Paradowski was editor-in-chief from 1997-1999. In 1998 he initiated alterations in the profile and cover design of the journal which were accepted by the Editorial Board. The title was changed to Advances in Clinical and Experimental Medicine. Articles in English were welcomed. A number of outstanding representatives of medical science from Poland and abroad were invited to participate in the newly established International Editorial Staff.
Prof. Antonina Harłozińska-Szmyrka was editor-in-chief in years 2000-2005, in years 2006-2007 once again prof. Leszek Paradowski and prof. Maria Podolak-Dawidziak was editor-in-chief in years 2008-2016. Since 2017 the editor-in chief is prof. Maciej Bagłaj.
Since July 2005, original papers have been published only in English. Case reports are no longer accepted. The manuscripts are reviewed by two independent reviewers and a statistical reviewer, and English texts are proofread by a native speaker.
The journal has been indexed in several databases: Scopus, Ulrich’sTM International Periodicals Directory, Index Copernicus and since 2007 in Thomson Reuters databases: Science Citation Index Expanded i Journal Citation Reports/Science Edition.
In 2010 the journal obtained Impact Factor which is now 1.179 pts. Articles published in the journal are worth 15 points among Polish journals according to the Polish Committee for Scientific Research and 169.43 points according to the Index Copernicus.
Since November 7, 2012, Advances in Clinical and Experimental Medicine has been indexed and included in National Library of Medicine’s MEDLINE database. English abstracts printed in the journal are included and searchable using PubMed http://www.ncbi.nlm.nih.gov/pubmed.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
